CLINICAL IMPROVEMENT IN PATIENTS WITH EXERCISE INDUCED PULMONARY ARTERY HYPERTENSION AFTER 6 MONTHS OF PHOSPHODIESTERASE-5 INHIBITORS OR ENDOTHELIAL RECEPTOR ANTAGONISTS OR BOTH

被引：0
|
作者：
Mannem, Santhosh R. [1 ]
Salamon, Jason [1 ]
Gunda, Sampath [1 ]
Iqbal, Muhammed [1 ]
Bhandari, Manoj [1 ]
Mazurek, Jeremy [1 ]
Zolty, Ronald [1 ]
机构：
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2014年 / 63卷 / 12期
关键词：
D O I：
10.1016/S0735-1097(14)61663-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1197-357
引用
收藏
页码：A1660 / A1660
页数：1
相关论文
共 33 条
  • [21] Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study
    Kuroda, Kazuhiro
    Akagi, Satoshi
    Nakamura, Kazufumi
    Sarashina, Toshihiro
    Ejiri, Kentaro
    Ito, Hiroshi
    HEART LUNG AND CIRCULATION, 2020, 29 (03): : 331 - 336
  • [22] MEDICATION ADHERENCE AND RISK OF HOSPITALIZATION IN PULMONARY ARTERIAL HYPERTENSION (PAH) PATIENTS TREATED WITH ENDOTHELIN RECEPTOR ANTAGONISTS (ERAS) OR PHOSPHODIESTERASE TYPE 5 INHIBITORS (PDE5IS)
    Hill, J. W.
    Lickert, C. B.
    Cole, M. R.
    Wade, R. L.
    Tsang, Y.
    Drake, W.
    VALUE IN HEALTH, 2017, 20 (09) : A620 - A620
  • [23] Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors
    Frantz, Robert P.
    Hill, Jerrold W.
    Lickert, Cassandra A.
    Wade, Rolin L.
    Cole, Michele R.
    Tsang, Yuen
    Drake, William, III
    PULMONARY CIRCULATION, 2020, 10 (01)
  • [24] Help-seeking patterns and funding strategies in patients with pulmonary arterial hypertension on phosphodiesterase-5 inhibitors: an orphan disease with effective but costly treatment
    Lim, Yinghao
    Maaroof, Siti Munawarah Bte
    Low, Ting Ting
    Kuntjoro, Ivandito
    Yip, James W. L.
    Tay, Edgar
    SINGAPORE MEDICAL JOURNAL, 2021, 62 (04) : 199 - 203
  • [25] Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis
    Cao, Fen
    Wu, Kun
    Zhu, Yong-zhi
    Jiang, Jun-jun
    Zhang, Gui
    Liu, Jun
    Xiao, Ping
    Tian, Yang
    Zhang, Wei
    Zhang, Sheng
    Hou, Feng
    Bao, Zhong-wu
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 9
  • [26] Do phosphodiesterase 5 inhibitors improve exercise capacity in patients with COPD associated pulmonary hypertension? (3P study)
    Goudie, Andrew
    Hopkinson, Pippa
    Lipworth, Brian
    Struthers, Allan
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [27] Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study
    Hjalmarsson, Clara
    Butler, Oisin
    Hesselstrand, Roger
    Holl, Katsiaryna
    Jansson, Kjell
    Klok, Rogier
    Radegran, Goran
    Soderberg, Stefan
    Kjellstrom, Barbro
    PULMONARY CIRCULATION, 2020, 10 (03)
  • [28] Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
    Hoeper, Marius M.
    Al-Hiti, Hikmet
    Benza, Raymond L.
    Chang, Sung-A
    Corris, Paul A.
    Gibbs, J. Simon R.
    Grunig, Ekkehard
    Jansa, Pavel
    Klinger, James R.
    Langleben, David
    McLaughlin, Vallerie V.
    Meyer, Gisela M. B.
    Ota-Arakaki, Jaquelina
    Peacock, Andrew J.
    Pulido, Tomas
    Rosenkranz, Stephan
    Vizza, Carmine Dario
    Vonk-Noordegraaf, Anton
    White, R. James
    Chang, Mikyung
    Kleinjung, Frank
    Meier, Christian
    Paraschin, Karen
    Ghofrani, Hossein Ardeschir
    Simonneau, Gerald
    LANCET RESPIRATORY MEDICINE, 2021, 9 (06): : 573 - 584
  • [29] Improved endothelial dysfunction after 6 months of multifactorial intervention with focus on exercise training in diabetic patients with coronary artery disease
    Sixt, S
    Peschel, T
    Halfwassen, U
    Diederich, K
    Schuler, G
    Niebauer, J
    EUROPEAN HEART JOURNAL, 2004, 25 : 454 - 455
  • [30] The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i)
    Pestana-Fernandez, Melani
    Rubio-Rivas, Manuel
    Tolosa-Vilella, Carles
    Guillen-Del-Castillo, Alfredo
    Colunga-Arguelles, Dolores
    Argibay, Ana
    Mari-Alfonso, Begona
    Marin-Ballve, Adela
    Pla-Salas, Xavier
    Chamorro, Antonio-J
    Castro-Salomo, Antoni
    Madronero-Vuelta, Ana Belen
    Sanchez-Garcia, Maria Esther
    Saez-Comet, Luis
    Gonzalez-Echavarri, Cristina
    Ortego-Centeno, Norberto
    Vargas-Hitos, Jose Antonio
    Todoli-Parra, Jose Antonio
    Trapiella-Martinez, Luis
    Lledo, Gema Maria
    Freire, Mayka
    Fonollosa-Pla, Vicent
    Simeon-Aznar, Carmen Pilar
    RHEUMATOLOGY, 2021, 60 (02) : 872 - 880
1234